USPH Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
U.S. Physical Therapy Inc (USPH) is not a strong buy at the moment for a beginner investor with a long-term focus. The technical indicators suggest a bearish trend, and the financial performance shows significant challenges with declining net income and EPS. While the company has potential for organic growth and margin expansion as noted by analysts, the lack of positive trading signals, recent bearish price trends, and absence of strong catalysts make it prudent to hold off on buying this stock right now.
The technical indicators for USPH are bearish. The MACD is negatively expanding (-0.716), the RSI is at an oversold level (16.935), and the moving averages are bearish (SMA_200 > SMA_20 > SMA_5). The stock is trading near its key support level (S1: 74.565), with resistance levels at R1: 81.578 and R2: 83.745. Additionally, the stock has a 70% chance to decline further in the short term (-0.8% in the next day, -3.38% in the next week, -6.25% in the next month).
Analysts see potential for organic growth acceleration and margin expansion due to strategic hospital alliances and improved Medicare rates.
The company's financial performance is weak, with a significant drop in net income (-182.87% YoY) and EPS (-182.69% YoY). Technical indicators are bearish, and options data reflects bearish sentiment. No recent news or congress trading data provides additional positive catalysts.
In Q4 2025, revenue increased by 12.35% YoY to $202.73 million. However, net income dropped significantly to -$6.55 million (-182.87% YoY), and EPS fell to -0.43 (-182.69% YoY). Gross margin improved slightly to 20.65% (+7.61% YoY), but overall profitability remains a concern.
Jefferies recently assumed coverage with a Buy rating and a price target of $102 (down from $110). Analysts highlight potential growth through strategic hospital alliances and favorable pricing environments. However, the reduced price target reflects tempered expectations.
